Failure of natalizumab to prevent relapses in neuromyelitis optica

Archives of Neurology

Volumn 69, Issue 2, 2012, Pages 239-245

  Kleiter, Ingo ^a,b   Hellwig, Kerstin ^b   Berthele, Achim ^c   Kümpfel, Tania ^d   Linker, Ralf A ^e   Hartung, Hans Peter ^f   Paul, Friedemann ^g   Aktas, Orhan ^f  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; BETA INTERFERON; MITOXANTRONE; NATALIZUMAB; RITUXIMAB; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DRUG DOSE ESCALATION; FEMALE; GERMANY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEROLOGY; TERTIARY HEALTH CARE; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUAPORIN 4; AUTOANTIBODIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROMYELITIS OPTICA; RECURRENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84856923074     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.216     Document Type: Article

References (44)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114. (Pubitemid 29442132)
2. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383-392.
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477. (Pubitemid 41186945)
4. Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;4(4):e133.
5. Kalluri SR, Illes Z, Srivastava R, et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010;67(10):1201-1208.
6. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006;63(7):957-963. (Pubitemid 44036296)
7. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
8. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol. 2010;67(9):1131-1136.
9. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68(4):473-479.
10. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272.
11. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13(2):256-259. (Pubitemid 46592781)
12. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007;252(1):57-61. (Pubitemid 44909191)
13. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008;255(2):305-307.
14. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol. 2009;62(3):167-170.
15. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75(16):1423-1427.
16. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67(8):1016-1017.
17. Polman CH, O'Connor PW, Havrdova E, et al AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
18. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743-747. (Pubitemid 43673151)
19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489. (Pubitemid 43958540)
20. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58(6):840-846. (Pubitemid 41746873)
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
22. Lee DH, Metz I, Berthele A, et al. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol Appl Neurobiol. 2010;36(7):685-687.
23. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(pt 11):2059-2069. (Pubitemid 27493740)
24. Sellner J, Cepok S, Kalluri SR, et al. Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. Neurochem Int. 2010;57(6):662-667.
25. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-1315.
26. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
27. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71(17):1350-1354.
28. Rinaldi L, Rinaldi F, Perini P, et al. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. J Neurol Neurosurg Psychiatry. 2010;81(12):1345-1350.
29. Wehner NG, Gasper C, Shopp G, et al. Immunotoxicity profile of natalizumab. J Immunotoxicol. 2009;6(2):115-129.
30. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007;130(pt 5):1224-1234. (Pubitemid 47355951)
31. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630-643.
32. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(pt 11):3072-3080.
33. Kivisäkk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72(22):1922-1930.
34. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology. 2009;73(20):1628-1637.
35. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443-1452.
36. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701-3706.
37. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004;63(12):2363-2370. (Pubitemid 40024351)
38. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63(3):390-396.
39. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964-968. (Pubitemid 44036298)
40. Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler. 2009;15(6):695-700.
41. Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. "Cloud-like enhancement" is amagnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol. 2009;66(3):425-428.
42. Saiki S, Ueno Y, Moritani T, et al. Extensive hemispheric lesions with radiological evidence of blood-brain barrier integrity in a patient with neuromyelitis optica. J Neurol Sci. 2009;284(1-2):217-219.
43. Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler. 2004;10(1):2-4. (Pubitemid 38100519)
44. Matiello M, Pittock SJ, Porrata L, Weinshenker BG. Failure of autologous hematopoietic stem cell transplantation to prevent relapse of neuromyelitis optica [published online March 14, 2011]. Arch Neurol. doi:10.1001/archneurol. 2011.38.